A5053563261- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Medical Imaging Techniques and Applications
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Frailty in Older Adults
- Economic and Financial Impacts of Cancer
- Sarcoma Diagnosis and Treatment
- Cancer survivorship and care
- Metastasis and carcinoma case studies
- Gastric Cancer Management and Outcomes
- RNA modifications and cancer
- Brain Metastases and Treatment
- Childhood Cancer Survivors' Quality of Life
- Cardiac tumors and thrombi
- Diagnosis and treatment of tuberculosis
Centre Hospitalier Universitaire de Grenoble
2015-2024
AstraZeneca (France)
2021-2024
Inserm
2017-2024
Université Grenoble Alpes
2017-2024
Centre National de la Recherche Scientifique
2017-2024
Institut pour l'avancée des biosciences
2019-2022
Institut de Biosciences et Biotechnologies
2019-2020
Hôpital Nord
2020
Centro Oncológico de Galicia
2020
European Organisation for Research and Treatment of Cancer
2019
IntroductionImproved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated radical intent. As a uniform definition of sOM is lacking, we developed and diagnostic criteria by consensus process.MethodsA pan-European multidisciplinary group was established. Consensus questions were built on the basis current controversies, definitions extracted from survey, cases systematic review. This statement formulated during meeting.ResultsIt determined that relevant...
Data regarding the role of anthracyclines and taxanes as first-line treatments metastatic angiosarcoma are limited.Records 117 patients who were treated with either doxorubicin or weekly paclitaxel reviewed.Seventy-five (64%) 42 (36%) single-agent doxorubicin. Patients in group older more frequently had angiosarcomas arising from skin. In group, 34 evaluable for response: 2 (6%) complete response, 8 (23.5%) partial 10 (29.5%) stable disease, 14 (41%) progressive disease. 68 9 (13%) 27 (40%)...
ObjectivesNivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on approaches following discontinuation nivolumab and the interest second course immunotherapy discontinuation. The aims this study were to describe pathways survival retreatment immunotherapy.Materials methodsThe analysis includes all NSCLC recorded in national hospital database, starting 2015-2016....
Treatment of malignant pleural mesothelioma (MPM) remains disappointing, although recent reports suggest that multimodality therapy including surgery may provide a significant survival benefit. The aims this single institution study were: to investigate clinicopathologic characteristics and potential prognostic factors in MPM patients, ascertain whether followed by adjuvant had an independent role.Retrospective review prospectively compiled computerized database all patients with evaluated...
Abstract Purpose: The effect of translesion DNA synthesis system in conferring cellular tolerance to DNA-damaging agents has been recently described. polymerase η (Pol η) is part this machinery and vitro models showed that it can overcome damages caused by cisplatin UV rays. aim the present study was investigate role Pol mRNA expression levels non–small cell lung cancer (NSCLC). Experimental Design: were evaluated real-time PCR (a) formalin-fixed paraffin-embedded biopsies 72 NSCLC patients...
Most patients with lung cancer are smokers and of advanced age. They therefore at high risk having age- lifestyle-related comorbidities. These comorbidities subject to treatment or even polypharmacy. There is growing evidence a link between cancer, medications. The relationships these entities complex. presence their treatments influence the time diagnosis, as well diagnostic strategy. On other hand, may have an impact on patient’s such renal failure, pneumonitis endocrinopathies. This...
Abstract Background At intensive care unit (ICU) admission, the issue about prognosis of critically ill cancer patients is clinical interest, especially after ICU discharge. Our objective was to assess factors associated with 3- and 6-month survival survivors. Methods Based on French OutcomeRea™ database, we included solid discharged alive, between December 2005 November 2013, from medical university hospital in Grenoble, France. Patient characteristics outcome at 3 6 months following...